Results 71 to 80 of about 15,072 (244)

Efficacy of a K+ Channel Agonist, XEN1101, For Preserving Contractility in Mouse Models of Hypokalemic Periodic Paralysis

Muscle &Nerve, Volume 73, Issue 4, Page 668-674, April 2026.
Pretreatment with an agonist of Kv7 potassium channels (XEN1101) protects the soleus muscle from a loss of force during a 2 mM K+ challenge, in a mouse model of hypokalemic periodic paralysis. ABSTRACT Introduction/Aims Effective management remains lacking for recurrent episodes of acute weakness in hypokalemic periodic paralysis (HypoPP).
Viktor Chanchykov, Sharon Iype, Marbella Quinonez, Fenfen Wu, Stephen Cannon   +4 more
wiley   +1 more source

Eplerenone attenuated cardiac steatosis, apoptosis and diastolic dysfunction in experimental type-II diabetes [PDF]

, 2013
Cardiac steatosis and apoptosis are key processes in diabetic cardiomyopathy, but the underlying mechanisms have not been elucidated, leading to a lack of effective therapy.
Ares-Carrasco, Sara, Barbas, Coral, Caro-Vadillo, Alicia, Egido de los Ríos, Jesús, Ferrarini, Alessia, Klett-Mingo, Mercedes, Lorenzo, Óscar, Picatoste, Belén, Ramírez, Elisa, Rupérez, Francisco Javier, Tuñón, José Luis Morales   +10 more
core   +3 more sources

Effect of eplerenone on aldosterone and von Willebrand factor levelsin patients with myocardial infarction and chronic kidney disease

Zaporožskij Medicinskij Žurnal, 2022
Aim: to study the levels of aldosterone and von Willebrand factor (VWF) in patients with Q-wave acute myocardial infarction (Q-AMI) and underling chronic kidney disease (CKD) using aldosterone antagonists. Materials and methods.
V. K. Tashchuk, O. S. Polianska, O. I. Hulaha   +2 more
doaj   +1 more source

Aldosterone as a renal growth factor [PDF]

, 2010
Aldosterone regulates blood pressure through its effects on the cardiovascular system and kidney. Aldosterone can also contribute to the development of hypertension that leads to chronic pathologies such as nephropathy and renal fibrosis.
Dooley, Ruth, Harvey, Brian J, Thomas, Warren   +2 more
core   +1 more source

A randomized controlled trial of eplerenone in asymptomatic phospholamban p.Arg14del carriers [PDF]

, 2023
Remco de Brouwer, Wouter P. te Rijdt, Edgar T. Hoorntje, Ahmad S. Amin, Folkert W. Asselbergs, Moniek G.P.J. Cox, Jeroen F. van der Heijden, Hans L. Hillege, Jacco C. Karper, Belend Mahmoud, Peter van der Meer, Anton Oomen, Anneline S.J.M. te Riele, Herman H.W. Silljé, Hanno L. Tan, Jan Peter van Tintelen, Dirk J. van Veldhuisen, B. Daan Westenbrink, Ans C.P. Wiesfeld, Tineke P. Willems, Paul A. van der Zwaag, Arthur A.M. Wilde, Rudolf A. de Boer, Maarten P. van den Berg   +23 more
openalex   +1 more source

Eplerenone inhibits aldosterone-induced CRP generation in rat vascular smooth muscle cells by regulating the MR-ROS-ERK1/2 signal pathway

European Journal of Inflammation, 2017
Atherosclerosis is a chronic inflammatory disease in the vessel wall. As a representative inflammatory cytokine, C-reactive protein (CRP) participates in the formation and development of atherosclerosis.
Xiaolu Zhang, Juntian Liu, Xiaoming Pang, Jingjing Zhao, Shouzhu Xu, Jing Zhao   +5 more
doaj   +1 more source

Comparative effectiveness of pharmacotherapy for heart failure with preserved ejection fraction: A systematic review and network meta‐analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 3137-3145, April 2026.
Abstract Aim Heart failure with preserved ejection fraction (HFpEF) presents a therapeutic challenge, characterised by a paucity of validated treatments. Emerging data suggest that targeting adiposity is central to HFpEF pathogenesis. We conducted an updated network meta‐analysis to compare the efficacy of emerging and established HFpEF therapies ...
Szu‐Han Chen, Yu‐Wen Tseng, Chi‐Jung Huang, Shu‐Mei Yang, Marat Fudim, Shao‐Yuan Chuang, Shih‐Hsien Sung, Hao‐Min Cheng   +7 more
wiley   +1 more source

Hypokalemic rhabdomyolysis: a rare manifestation of primary aldosteronism [PDF]

, 2015
Rhabdomyolysis is a rare presentation of hypokalemia, although muscle weakness is a well-known manifestation of hypokalemia. Primary aldosteronism is characterized by hypertension, suppressed plasma renin activity, increased aldosterone excretion and ...
CONCISTRE, ANTONIO, FIACCO, FEDERICA, LETIZIA, Claudio, MARINELLI, CRISTIANO, MITTERHOFER, Anna Paola, PETRAMALA, LUIGI, TINTI, FRANCESCA, UMBRO, ILARIA, ZAVATTO, ASSUNTA, ZINGARETTI, VIVIANA   +9 more
core  

Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: A systematic review and meta-analysis [PDF]

, 2016
Background: Hypertension and proteinuria are critically involved in the progression of chronic kidney disease. Despite treatment with renin angiotensin system inhibition, kidney function declines in many patients.
Boesby, L. (Lene), Currie, G. (Gemma), Delles, C. (Christian), Edwards, N.C. (Nicola C.), Ferro, C.J. (Charles J.), Fujita, T. (Toshiro), Jardine, A.G. (Alan G.), Lindhardt, M. (Morten), Mark, P.B. (Patrick B.), Meiracker, A.H. (Anton) van den, Ohtsu, H. (Hiroshi), Oveisi, S. (Sonia), Preiss, D.J. (David J.), Rossing, K., Saklayen, M.G. (Mohammad G.), Taylor, A.H.M. (Alison H. M.), Townend, J. (Jonathan)   +16 more
core   +1 more source

The urinary albumin‐to‐creatinine ratio can direct personalized prevention and treatment for cardiovascular and chronic kidney disease

Journal of Internal Medicine, Volume 299, Issue 4, Page 444-466, April 2026.
Abstract Increased urinary albumin excretion is a strong predictor for cardiovascular events in persons with and without decreased glomerular filtration rate and can be assessed with the urinary albumin‐to‐creatinine ratio (UACR), which is a selective, sensitive, and convenient method for patients.
Holly J. Kramer, George L. Bakris
wiley   +1 more source